Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.
Related

Jessica Jackley,
Kiva
‘What If?’ Changes the World [Entire Talk]
Asking “What if?” can change the whole story.
Video
47 minutes
Jessica Jackley,
Kiva
‘What If?’ Changes the World [Entire Talk]
Asking “What if?” can change the whole story.

Sarah Lamaison,
Dioxycle
Climate Tech Insights [Entire Talk]
Climate tech entrepreneurs are an essential part of reducing and removing carbon emissions.
Video
47 minutes
Sarah Lamaison,
Dioxycle
Climate Tech Insights [Entire Talk]
Climate tech entrepreneurs are an essential part of reducing and removing carbon emissions.

Michelle Lee,
Medra
From Conviction to Company [Entire Talk]
From finding conviction in their ideas to deciding how to grow, detect founders face many decisions.
Video
49 minutes
Michelle Lee,
Medra
From Conviction to Company [Entire Talk]
From finding conviction in their ideas to deciding how to grow, detect founders face many decisions.